France Biotech reports on dynamism of nation's life sciences industry

6 June 2013

France Biotech, the association of French entrepreneurs in the Life Sciences, published the 11th edition of its annual study, titled Panorama of the Life Sciences Industry, which reports on the international and domestic industry trends in 2012/2013. This year, 186 French companies took part in the study.

This study underlines the dynamism and wealth of our industry, which affects a number of sectors, ranging from medical devices and therapeutics to green and industrial biotechnology (such as biofuels and biomaterials). With less R&D investment than the pharmaceutical industry, this sector is able to bring more products into clinical phase trials. The fact that the industry achieved a level of maturity in 2011 was confirmed in 2012 by the continuation of external growth and consolidation activities by French companies. The young companies represent the growth potential for the industry of tomorrow. It is time for our government and industry leaders to put the necessary resources behind this process.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight



More Features in Biotechnology